Hot Features
Premium
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Impel Pharmaceuticals Inc | IMPL | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.2411 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.2411 | 0.2411 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 0.19 - 2.87 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 0.2411 | USD |
Impel Pharmaceuticals Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 5.7M | 23.74M | - | 12.65M | -106.31M | -4.48 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Impel Pharmaceuticals News
| Date | Time | Source | News Article |
|---|---|---|---|
| 4/09/2024 | 15:17 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
| 2/15/2024 | 23:15 | Edgar (US Regulatory) | Form EFFECT - Notice of Effectiveness |
| 2/14/2024 | 16:21 | Edgar (US Regulatory) | Form S-8 POS - Securities to be offered to employees in.. |
| 2/14/2024 | 16:16 | Edgar (US Regulatory) | Form POS AM - Post-Effective amendments for registration.. |
| 2/14/2024 | 16:15 | Edgar (US Regulatory) | Form 8-K - Current report |
| 1/02/2024 | 15:23 | Edgar (US Regulatory) | Form 8-K - Current report |
| 12/18/2023 | 07:31 | Edgar (US Regulatory) | Form 8-K - Current report |
| 12/04/2023 | 05:05 | Edgar (US Regulatory) | Form 8-K - Current report |
| 11/14/2023 | 15:01 | Edgar (US Regulatory) | Form 8-K - Current report |
| 11/02/2023 | 16:20 | Edgar (US Regulatory) | Form 8-K - Current report |
| 10/16/2023 | 15:33 | Edgar (US Regulatory) | Form 8-K - Current report |
| 10/05/2023 | 16:19 | Edgar (US Regulatory) | Form 424B5 - Prospectus [Rule 424(b)(5)] |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical IMPL Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 6 Months | 0.29 | 1.06 | 0.19 | 0.6319163 | 1,607,163 | -0.0489 | -16.86% |
| 1 Year | 1.65 | 2.87 | 0.19 | 0.9370588 | 982,633 | -1.41 | -85.39% |
| 3 Years | 14.30 | 34.75 | 0.19 | 4.77 | 362,815 | -14.06 | -98.31% |
| 5 Years | 15.31 | 34.75 | 0.19 | 4.87 | 365,861 | -15.07 | -98.43% |
Impel Pharmaceuticals Description
| Impel Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformative therapies for patients suffering from diseases with high unmet medical needs, with an initial focus on diseases of the central nervous system. The company is developing an approach to drug delivery that administers specific formulations of drugs deep into the vascular-rich upper nasal space, a gateway for therapeutic administration of a versatile range of molecules and formulations. |
